Member Info for Yorkshireboy

Krautyankee totally agree with your post. Have been undecided whether to reinvest in MTFB and posted yesterday (13th April 11:49) requesting advice/help in answering certain questions. Unfortunately, none has been forthcoming, therefore, I can only surmise that there are no positive answers.

Another question, why hasn’t MTFB etc, jumped on the bandwagon and constructively manipulated their relationship/collaboration with ‘Lamellar Biomedical’. This is a great opportunity for them and if they did, the share price would soar. One might ask, does the collaboration continue to exist!

Moneymunch (today 10:13) states ‘it also in preclinical trials since October with the US Army WRAIR’. If he had visited:- https://adisinsight.springer.com/drugs/800018080 (Most Recent Events Section) he would, have seen the following;
31 Oct 2019 Motif Bio entered into research agreement with Walter Reed Army Institute of Research to conduct preclinical testing
08 Nov 2019 Motif Bio plans a preclinical study for wound infection
18 Mar 2020 Motif Bio ceased all its operations and sold its assets

I don’t have a problem with posters having their own opinions and sharing their views. But if they ramp without evidence and investors lose money (although no one makes a person invest) then they must live with their conscience (if they have one).

IMHO it would appear that this is being ‘ramped’ beyond belief without genuine evidence. Please re-read Krautyankee (10:08) post. Research, Research and Research again, don’t get ‘sucked’ in by the few.

I, like ‘Ivyspivey’ and many others, lost heavily on the St Valentine’s Day massacre and ultimately sold out of this reprehensible company (a few months ago) with a substantial loss. I am not trying to rain on anyone’s parade and believe it or not, would love to see some of the LTH recover some of their losses and for the many sufferers of this terrible virus have a viable treatment. In fact, I actually thought about reinvesting last Thursday, but then stood back and as the song goes; https://www.bing.com/videos/search?q=once+bitten+twice+shy&view=detail&mid=5BADAF2EE97CA1648A0A5BADAF2EE97CA1648A0A&FORM=VIRE0&PC=LCTS&cc=GB&setlang=en-GB&PC=LCTS&cvid=f9dd9beec5954bffb66eb5c34b5e849e&qs=LS&nclid=60F1C024A8D17225C3FA9FA8215AEBE3&ts=1586772505365
Thought don’t get sucked in and get bitten again, consequently try and do some further (as we are always being advised) research but haven’t had much luck. The following list isn’t extensive, but if anyone can help me, I would be eternally grateful: -
Has anyone seen/heard of any communication relating to the ‘the collaboration between MTFB and Lamellar Biomedical’ since it was announced back in May 2019’?

Has there been any information (official or otherwise) regarding the proposed ‘in vivo pre-clinical study evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections’?

Is there any material/reference to the partnership/collaboration on ‘Lamellar Biomedical Ltd’ website or has there been any previous reference on Motif Bios website?

If not, why not?

For those who are interested, I did come across the following regarding ‘The agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology’.
RNS Number: 9200Q Motif Bio PLC, 24 October 2019
Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.
https://adisinsight.springer.com/drugs/800018080

Although, without proof that they are still in a substantive partnership I am still hovering. I thank you in anticipation and keep safe, GLA.

Soupdragon78 unbelievable coincidence, although, he may just have had a lapse of memory. They do say that certain conditions affect short term memory, although (if it is him) it must be an extreme issue. Aprox 2hrs ago Trader…@Eagle _Trader01 (London, England Joined September 2017,185 Following 31 Followers) posted: - #NFX Hearing RNS is getting typed up. Get ready for the Japan Deal BOOOOOM.
https://twitter.com/Eagle_Trader01/status/1247834360646176769

By the way good moves, which one is you. If this is not you, my apologies if it is, please, don’t lie and at least have the guts to own up!

I can not complete this post without referring to ‘oldblue1973’ post at 08:42 ‘ok think about this....this was probably some guys last chance of beating prostate cancer and apparently this stuff actually works now because off your sack the board rubbish the trails been halted.....now there is probably some boy or girl out there who has been balling there eyes out because they have been told there fathers last chance at cancer has been stopped
I hope you all happy’
Unfortunately, this is a very imprudent comment, as he has not considered the stage of Val201 development, which obviously means at this time no one can benefit by Val201. Obviously, he must not only be discombobulated, but oblivious to the psychological damage his statements can cause, if he is spreading such rumours.

I truly believe change must happen.
Have a good w/e and GLA

It is very rare that I would be critical of any members post or opinion on any BB as I believe every person has the right to their own views. People usually invest in bio companies for financial/ altruistic reasons or both and these should be respected. However, in my opinion the situation on here is extremely divisive (which is not a problem), but they are becoming more emotive and illogical (not researched based) and without relevant reference to fact.
The fact is Valirx has just completed (Actual Primary Completion Date: January 27, 2020)
a phase I/II clinical trial (Study Start Date October 2014) for Val201.
A Phase1/11 clinical trial is a study that tests the safety, side effects, and best dose of a new treatment. Phase I/II clinical trials also test how well a certain type of cancer or other disease responds to a new treatment. In the phase II part of the clinical trial, patients usually receive the highest dose of treatment that did not cause harmful side effects in the phase I part of the clinical trial. Combining phases I and II may allow research questions to be answered more quickly or with fewer patients. Also called phase 1/phase 2 clinical trial.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/phase-i-ii-clinical-trial
It has taken over 5 years for completion of this initial phase and, only enrolled 18 participants when they were estimated to enrol 25 participants. To date ‘No Study Results have been posted for this Study’.
https://www.clinicaltrials.gov/ct2/show/results/NCT02280317?term=NCT02280317&cond=Cancer&draw=2&rank=1
If they can achieve ‘proof of concept’ and regulatory approval for continuation into phase III clinical trials, what will be required and how long will it take? On the 18th December 2017 it was stated, (VAL201 is currently in Phase I/II clinical trials at UCLH for prostate cancer.), the company now needs phase II studies with a reasonable number of patients after a good dose ranging result to attract big name pharmaceutical interest to pay for the expensive phase III clinical trials.
https://contrarianinvestor.net/posts/2017/12/18/valirx-moves-up-sharply-on-news-that-regulator-will-allow-dose-ranging-study-for-val201
Who will fund this expensive and time consuming phase? Regarding Dr George Morris stating, that he will not seek re-appointment as a director of the Company following the completion of the VAL201 trial and its regulatory approval, does he mean Phase I/II or ultimate completion. If it’s the later, he will be a director for a very long time. In addition, I know that there have been repetitive statements regarding the competence of the Bod. I can only state that if I had performed (during my 49 years of professional responsibility) with such dereliction of duty and little understanding and appreciation of my ‘duty of care’. I would not have been employed for very long, but would also be void of any compassion.
Cont

Non-automatic licenses are a trade administration procedure "fully compatible with the rules of the World Trade Organization (WTO), which sets a period of 60 days in which the Industry Secretariat must be issued so that this request does not respond to speculative manoeuvres. "
The government analysed in the last hours that when President Alberto Fernández took office, oil was trading at US $ 63 a barrel and began a rise to exceed US $ 70 in January, to face a drop below US $ 60 and enter the sharp decline in recent days to touch US $ 32.
"This volatility is a problem to think about investing in a sector with great oil potential but with different costs than the Middle East," said Kulfas.
Regarding the possibility of implementing the so-called "Creole barrel", the minister said: "We are not Saudi Arabia in our cost structure, and we have to think about how we locate a price that is not shot at us and is reflected in the pump."
"But neither can we accompany a very sharp drop that causes many wells to go out of production, losing jobs in oil and in the entire service industry associated with activity throughout the country," he added.
Finally, he assured that the government observes oil and gas "not as a merely extractive activity, but behind it is a large chain of suppliers, from national SME industries throughout the country that produce equipment and provide services generating a lot of employment", for which acts "as a lever for the long-term development of the Argentine economy".’
https://www.telam.com.ar/notas/202003/439500-gobierno-nacional-licencias-no-automaticas-importacion-hidrocarburos-crudo-gas-oil-nafta.html

GLA
YB

Brasso3 thanks for the ‘excellent’ link. Appears that the ‘Sun’ is about to shine on the Argentinian oil etc sector. As it looks like the Argentina government are about to take action by protecting their energy sector. I have taken the liberty of translating it (sorry have included the full text) so fellow posters don’t have too. Just hope it’s been done correctly.
‘The national government today ordered the application of Non-Automatic Licenses (LNA) for the import of crude oil, gas oil and naphtha in order to avoid speculative manoeuvres that affect local production, within the framework of the volatility of the international price of crude oil.
The measure was ordered through the Ministry of Productive Development led by Matías Kulfas, who established that aviation fuels, virgin naphtha, liquefied petroleum gas (LPG) and fuel oil for electrical energy sources, boilers or furnaces will be excluded from the provision.
Government sources informed Télam that the objective of the measure is "to guarantee national production and employment for Argentines," given the drop of up to 35% that WTI and Brent crude accumulated during the days of Friday and Monday.
With that same objective, the hydrocarbon-producing provinces nucleated in the Ofephi will hold a meeting tomorrow afternoon in Buenos Aires with the Secretary of Energy, Sergio Lanziani, and the Undersecretary of Hydrocarbons, Juan José Carbajales.
There, it is anticipated that the provinces will raise the need to implement a support price for local crude oil of around US $ 50 a barrel, as the Minister of Energy and Natural Resources of Neuquén, Alejandro Monteiro, expressed today.
In fact, tomorrow's meeting can be considered the starting point of the call that the Ministry of Productive Development will carry out for a round of consultations with unions and companies to monitor the situation and evaluate next steps for the hydrocarbon sector.
After disclosing the implementation of non-automatic licenses, Minister Kulfas said that "the fall in the international price affects part of production", and given the evidence that "Vaca Muerta has higher costs, doing nothing would mean that certain wells stop producing ".
"We are thinking of measures to take care of jobs, production and have a proactive attitude in that regard," said the official, noting that "the great volatility of the oil market these days raises many questions regarding how to handle the situation in the future."
In ratifying the entry into force of the LNA, the minister said that the government's idea is "to have a series of measures in consensus with the unions, the producing provinces and companies to sustain the level of production seeking to sustain the jobs that exist today. "
TO BE CONTINUED

it may be beneficial to take 5 minutes (of what may be a busy/stressful schedule) and visit/revisit the following ‘Proactive investors’ article from December 2019.

‘Nuformix says it has a "good shot" at doing something "really meaningful" with lung disease drug’
https://www.proactiveinvestors.co.uk/companies/news/909294/nuformix-says-it-has-a--good-shot--at-doing-something--really-meaningful--with-lung-disease-drug-909294.html

In response to some previous posts, obviously, all posts on BB’s are individual posters views (although they should at least be invested in the company (in my opinion)), unless substantiated by proven research etc. They are entitled to their opinions and should be viewed as such. No one can make us invest (unless in my case it’s ‘our lass’) and if we make an unwise investment, only ourselves can be held accountable for our decision and should not blame others. I also think there are some extremely well-informed and experienced investors on this BB whom I respect and take on board what they share. Nevertheless, it is essential we do our own research and are responsible for our own actions.

Good luck to all and hopefully NFX unique development continues unabated and allows those investors who are restricted with an unbalanced work/life balance (like me) to reap the benefits of financial stability and in my case, early retirement.
YB

San Francisco, CA -- (SBWIRE) -- 02/27/2020 -- Global Epigenetics Market: Overview.
The global epigenetics market is expected to grow at a fast paced CAGR in the next few years, owing to factors such as extensive use in the research of developmental and disease process, and growing importance of Life Science. Increasing incidences of cancer and other life-threatening diseases will also drive the growth of the global epigenetics market. Epigenetic changes are extensively used in cancer research for studying tumor biology as well as to develop therapeutic drugs to fight cancer.

In addition to North America, it is estimated the developing economies in Asia Pacific will emerge as lucrative markets for epigenetics.
Global Epigenetics Market: Competitive Landscape
Illumina, Diagenode, Abcam, CellCentric Ltd, Merck, Thermo Fisher Scientific, Zymo research, Qiagen, Chroma Therapeutics Ltd,Syndax Pharmaceuticals, Inc., Sigma-Aldrich Corporation, Eisai Co. Ltd, Oncolys Biopharma Inc., Novartis International AG, and Valirx Plc are some of the leading players within the global epigenetics market.
www.sbwire.com/press-releases/epigenetics-market-scope-summary-overview-research-methodology-and-forecast-to-2025-cellcentric-ltd-merck-thermo-fisher-scientific-1279673.htm

Just an addendum to the recent admirable posts: -

Large Number of women with transvaginal mesh require surgeries years later. (February 19th, 2020)
'An alarmingly high percentage of women who received transvaginal mesh implants to treat pelvic organ prolapse (POP) require additional surgeries years after being implanted with the devices, suggesting that problems with the devices won’t end anytime soon despite the removal of mesh for POP from the market last year.’
https://www.beasleyallen.com/news/large-number-of-women-with-transvaginal-mesh-require-surgeries-years-later/

’Empowering Surgeons’ which includes some excellent testimonials.
https://www.armsmedical.com/surgeons/

Once outstanding issues are resolved and positive news arrives, how can this remain so cheap. Surely the SP must ‘soar’, but please DYOR and good luck.

Continued
Although, if its lack of confidence due to the fluctuating SP, I suggest the following: - ‘Things Can Only Get Better’
https://www.youtube.com/watch?v=7W3yz6abJkU
Please DYOR and enjoy the sing along.
Good Luck

I just thought I would remind investors why the appointment of Dr Muhunthan Thillai to Nuformix's Scientific Advisory Board was a prodigious achievement. At the time NFX stated: - ‘The appointment reflects progress made with Nuformix's NXP002 programme as a treatment for Idiopathic Lung Fibrosis (IPF) as it finalises its clinical development plans.

Muhunthan stated: - "It is a pleasure to be joining the Nuformix team at this point. The data generated to date in human IPF tissue slices versus current therapies demonstrates real promise in preventing disease progression and extending life free from side effects. Current therapies lack meaningful efficacy and their side effects can be so severe that some patients elect to stop treatment. Nuformix's approach offers the potential to move rapidly into clinic and allows us to explore other unmet needs in interstitial lung disease together."
Dan stated: - ‘His in-depth understanding of patients' needs, and the short-comings of existing therapies will enable Nuformix to identify how our NXP002 programme can offer greatest benefit for his patients. Muhunthan has already contributed to numerous IPF clinical studies and is currently developing new technologies and novel imaging biomarkers that improve assessment of disease progression. On top of this, he is highly respected by his peers and well connected with the major academic and pharmaceutical players in IPF.’
RNS Number: 4774L Nuformix PLC 06 September 2019.

In addition to Mars1 excellent post, I just thought I’d add the following morsel: -
Dr Muhunthan Thillai is one of 2 Directors of ‘Qureight Ltd’ which was founded in 2018 by 2 Cambridge doctors. Their platform enables analysis of images and data from multiple sources to better model diseases and assist with clinical trial endpoints.
Recently, their company has made it onto the respected 2020 Confinitive: - #21toWatch, shortlist.
https://www.cofinitive.com/21towatch/
Out of hundreds of entries received, 246 qualified candidates made it onto a longlist, which has now been whittled down to a shortlist of 56, featuring a dynamic mix of people, companies and ‘things’. https://www.cambridgeindependent.co.uk/business/21towatch-shortlist-of-people-companies-and-things-revealed-9099373/
The #21toWatch list will be divided into innovative and trailblazing people, companies and ‘things’ that are en route to being industry game-changers locally, nationally and globally.
https://www.cofinitive.com/21towatch/companies/

Since being invested, I have always had the greatest respect for Dan and the organisation and the prospective rewards it will deliver. Not only to investors but science/pharmaceutical development and its ultimate altruistic/therapeutic benefits. Therefore, have no intention of diluting my holding, however, I have no problem if fellow investors wish to do so, hey ho it’s their choice and they must have their reasons.

Outstanding Chinese payment being paid Friday (CNY), however, there’s a change in payment plan. Instead of direct payment to NFX, they’re sending it in Little Red Envelopes (LRE) to all active investors as per Chinese tradition, if they’ve got enough LRE’s.
Sorry just heard it’s ’Fake News’, but am I bothered, no. The payment will arrive at some point if not Friday and all investors will benefit, it also gives us more opportunity to ‘top-up’ at a lower Sp.

Happy CNY.
YB

As shown by the excellent video posted by Boom123 today, there are significant issues associated with Urogynaecological mesh which is used to treat stress incontinence and pelvic organ prolapse. The very same product used in vaginal mesh surgery currently facing a number of lawsuits worldwide has been, and is currently being used, in hernia operations.
https://www.nhsnegligence.co.uk/hip-knee-spine-implants/hernia-mesh-implants/

As highlighted by the video a safe, effective and endorsed alternative is urgently required and that is already available as most investors in TRX and the medical profession are becoming more and more aware. I.e.: - dCELL® technology A Decellularised Dermal Allograft is used to Manage a Patient's Soft Tissue Defects. Intended to be used to provide reinforcement, repair, or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument. female pelvic medicine & reconstructive surgery.

Posters on BB’s generally advice actual/potential investors to do their own research and quite rightly so. Consequently, I try to stick to this principle and following due diligence (before my initial investment last year), I could not believe the low SP of this organisation.

During this process I came across the inventors, Eileen Ingham and John Fisher CBE (UK) and thought I would post some links (for others who may be interested) which I found useful regarding the evolution of this exceptional product and thereby my subsequent investment.

Tissue Regenix featured on Discovery Channel (2016)
https://medical-technologies.co.uk/news-post/tissue-regenix-to-feature-on-discovery-channel/
Vote for inspiring professors’ cell-free tissue invention (2018)
https://medical-technologies.co.uk/news-post/vote-for-inspiring-professors-cell-free-tissue-invention/
Finalists for the European Inventor Award 2018
Invention: Decellularisation for regenerative medicine
https://www.epo.org/learning-events/european-inventor/finalists/2018/ingham.html

Following my initial investment, I have ‘topped up’ as and when I can. The last being yesterday as I am confident it will not remain at these levels for much longer.

Have a good day and good luck to all
YB

Thanks for pointing out my miscalculation Chinsontour . Sorry I didn't mean to mislead anyone but have learned my lesson i.e. don't use the 'lads' scientific calculator after an early liquid lunch, from now on I'm going to stick to the trusted abacus! Definitely won't affect my mood tomorrow (most depressing day of the year) as 300% + and 100% + overall, is still a great outcome and there's plenty more to come.
Working from home tomorrow so finishing off a good day with a couple of fine malts.
Cheers all, sit back and enjoy the ride, but make sure you're well strapped in.
Goodnight from an IT/Maths dinosaur.

Woke up this morning to a crisp and sunny day and despite the usual aches and pains I was looking forward to a pleasantly relaxed day. My joy at being alive was highlighted when I reviewed a couple of my investments, especially NFX. I’m not going to repeat what has already been excellently emphasised by numerous posters on here (albeit occasionally repetitive) but because this coming week is the anniversary of my initial investment in this sensational company.

Although I performed due diligence, I still count myself extremely fortunate (looking back) to have taken this first step and thankfully continued investing when I could over the year. That initial 2.15p per share investment has risen by aprox 430% (Wow), although, I stand to be corrected as my maths may not be the best. As I’ve added more, my average has increased, but I have still amassed an overall increase of over 200% (WOW). Everyone has their own strategy, whether buying or selling, and some will believe they are ‘experts’ and try to influence others and if a posters ‘strategy’ doesn’t fit with their ‘model’, can be quite judgmental. Fortunately, this doesn’t happen often on this BB and I try to learn from what has been some excellent information/advice. However, saying that I try to stick to my own philosophy, as its me pressing the ‘button’ and then I can’t blame anyone else.

Apparently, tomorrow (third Monday in January) is the most depressing day of the year, according to British psychologist, Cliff Arnall. Personally, I will be ecstatic as I believe we are on the ‘cusp’ of a momentous (NXP 1, 2, 3 & 4) year, which will hopefully dwarf my initial buys % increase. Sorry for saying this but in fact, (being a canny Yorkshire lad) I wouldn’t mind an initial SP fall, so I can continue to increase my holding, at as cheap a price as my last ‘top Up’ in December.

However, I don’t think I’ve a hope in hell of this happening. Therefore, took advantage to invest in another company that’s evolved out of the University of Leeds (where Dan & Joanne obtained their PhDs) at what I feel was an extremely cheap price. Thankfully they’ve already increased by over 50%, but time will tell, as shares go up & shares go down. Also, what do I know, I’m only a simple Yorkshire Boy who made a disastrous investment in MTFB!
Have a marvellous week and NFX investors shouldn’t have anything to feel depressed about tomorrow. Nor should future patients who will benefit by receiving NFX therapeutic/medicinal developments.
Cheers YB

The only thing I can guarantee is tax, death and our ‘lass’ requesting more!!!! Especially, not correctly forecasting the performance of the ‘Stock Market’. This can happen to even the best media tipsters, as evidenced by the ‘‘Midas’ (The Mail on Sunday) columnist Joanne Hart ‘Our Shares Guru with the Golden Touch’’. On Sunday 29th December she reviewed her three top tips for 2019, made last December. One was personally poignant, Motif Bio (MTFB). Therefore, at the end of another year/decade, I decided to have a quick review of my portfolio, comparing two companies (MTFB & NFX) which I started investing in, January 2019.

I regularly read BB’s but am a hesitant poster as there are more knowledgeable/educated posters in Stocks and Shares, than me. Although, occasionally (because, I’m an opinionated Yorkshire Lad) I like to share my views but try to present fact and hope it’s not interpreted as ‘ramping/de-ramping’, which I detest. Although emotions may surface, as I lost a substantial amount of good beer/wine/whiskey money on conclusion of my ‘affair’ with MTFB. I do not blame anyone other than myself for my disastrous financial outcome, no one forced me to press the button on building up a sizeable stake. Unfortunately, as (apparently, I am told) in many affairs I was lured into a false sense of security, did not apply due diligence and allowed my judgement to be clouded, being seduced by the potential reward.

Fortunately, I have not allowed this to happen with NFX, who have an excellent BoD (MTFB hasn’t), vastly experienced in their relevant scientific areas (MTFB isn’t), understand fiscal responsibility (MTFB doesn’t) and have ‘skin’ in the game (MTFB doesn’t). As we know, NFX aren’t a ‘one trick pony’ (MTFB is), have several concepts and are involved in numerous actual and potential collaborations (MTFB doesn’t) etc etc etc.

The moral I believe is, anyone can make a miscalculation and hopefully I will not do this again but can’t guarantee I won’t give into temptation. However, I have made substantial changes in my investing philosophy following this disastrous experience, by continuing my new ‘affair’ and organically growing my investment in Nuformix, with open eyes. I believe (sorry, here comes that ‘ramp’) this is as near as I will get to a splendid outcome. Not only financial but seeing others who will helped by NFX innovations. However, one must exercise one’s own judgement.

Have a wonderful New Year and here’s to a prestigious new decade.

By the way it’s money ‘our lass’ loves, so no mention of MTFB!

https://www.mddionline.com/tissue-engineering-market-be-worth-115-billion-2022

Happy New Year
YB

Sorry should have included the Link: -

"Company lifestyle share"

https://www.investorschronicle.co.uk/shares/2019/12/13/avoid-aim-s-traps/

Quote
'Placings
Equity raises are a necessary evil on Aim, as ‘growth’ companies often require cash to develop projects and invest in the business. However, many of these companies are not growth companies, but lifestyle vehicles for the directors. What may start out as an exciting dream to build a business eventually ends up in failure, but the directors have then become accustomed to increasingly higher salaries despite the share price going increasingly lower. A turkey doesn’t vote for Christmas – and so they hold on to their positions as long as they can. All of this, of course, is funded by the retail investor.
The company is a vehicle that pays the directors' salaries. It also pays the Nomad. It pays the broker (which may also be the Nomad), and it pays the PR agency. All of these parties, including the directors, have an interest in the company continuing, because without it they are all out of jobs. Therefore, there is always a new story or a new project to invest in – so long as retail investors continue to fund story stocks then the company will continue. If you are going to invest, it’s worth checking how much the directors have taken out of the business and how much of their own capital they’ve put in. Nil-cost options do not count – this is simply transferring shareholder cash into the directors’ pockets.'
Is Scott right or wrong!